Source: Socialist Republic of Vietnam
In the first phase of the human trials, selected volunteers aged 18-50 will receive two intramuscular injections of the vaccine, with a period of 28 days between the twoinjections. The first phase will span from December to February 2021.
The second phase of the trial vaccination will run from February to August 2021 with the participation of 400-600 volunteers aged from 12-75.
Prior to the clinical trials, the Nanocovax vaccine has been injected in mice and monkeys with very good results.
According to a representative from Nanogen, if all goes well, the vaccine clinical trials will be completed in about four months. After that, researchers will consider a plan to include the vaccine in mass vaccination.
In addition, based on its technology, Nanogen can produce up to 20 million doses of vaccine per month.